Products - Chronic kidney disease | Topic | NICE

Showing 7 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sibeprenlimab for treating IgA nephropathy [ID6604]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atrasentan for treating primary IgA nephropathy [ID6558]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [TSID12258]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Iptacopan for treating primary IgA nephropathy [TSID12248]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC